Clinical Trial Update: Huperzine for Cognitive and Functional Impairment in Schizophrenia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating huperzine for cognitive and functional impairment in schizophrenia has completed. The study was sponsored by Biomedisyn Corp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Huperzine (Huperzine A)

Snippet

Sponsor: Biomedisyn Corporation | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED